Benjamin Maynor

Ben is the Senior Vice President, CMC at Orna Therapeutics, where he is responsible for Chemistry, Manufacturing, and Controls (CMC).

Prior to joining Orna, Ben worked at Liquidia Technologies, where he co-invented Liquidia’s platform particle technology and led pipeline product development. As part of his role at Liquidia and its spin-out company, Envisia Therapeutics, he initiated several new technology initiatives and product development programs in ophthalmology, pain management, pulmonary hypertension, infectious disease, and vaccines. Over his 15 year tenure at Liquidia, he held a variety of roles including Senior Vice President, Research and Development, where he led platform technology, pharmaceutical development, analytical development, and nonclinical development activities for early and late-stage products.

Ben received a Ph.D. in Chemistry from Duke University, where he focused on nanofabrication, nanostructure synthesis, and materials chemistry. He has co-authored over 20 peer-reviewed publications in the fields of nanotechnology, colloid science, and drug delivery and has been a co-inventor on several patents and patent applications in the fields of nanotechnology and drug delivery.